N2OFF (NITO) Stock Price, News & Analysis

N2OFF, Inc. (NASDAQ: NITO) is described in its public communications as a clean tech and cleantech company engaged in sustainable solutions for energy and agri-tech. According to multiple company announcements, N2OFF focuses on integrated activities that touch renewable energy, greenhouse gas emissions reduction, and safety and quality solutions for the agri-tech market. The company’s shares trade on the Nasdaq Capital Market under the symbol NITO.

Over time, N2OFF has outlined a business profile that combines renewable energy investments with agri-food and biotechnology interests. Earlier descriptions referenced N2OFF as an agri-food tech company dedicated to sustainable solutions for the plant-based food industry, operating through segments that included pathogen prevention and N2O emissions global warming solutions. More recent disclosures emphasize cleantech and solar energy assets, while also highlighting majority and full ownership stakes in specialized subsidiaries.

Renewable energy and RTB solar asset strategy

N2OFF consistently describes itself as mainly engaged in European Union–based solar assets using a Ready to Build (RTB) business model. Company news releases state that N2OFF is the lead investor in four solar projects in three different EU countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd. Through a loan and partnership structure with Solterra and related entities, N2OFF participates in the development of large-scale solar photovoltaic and battery energy storage projects.

Public updates describe a flagship solar PV project in Melz, Germany, and battery energy storage system (BESS) projects in Sicily, Italy, as part of this portfolio. N2OFF has reported providing loan funding and additional capital to support development work, including studies for optimizing battery storage facilities. These activities are presented by the company as part of a capital-efficient approach to advancing projects toward RTB status and potential monetization.

Biotech and precision oncology via MitoCareX Bio Ltd.

Through SEC filings and press releases, N2OFF reports that it completed the acquisition of MitoCareX Bio Ltd. (“MitoCareX”), which then became a wholly owned subsidiary of N2OFF. The company describes MitoCareX as a biotechnology and drug discovery business focused on cancer therapeutics and other potential diseases and disorders through targeting the mitochondrial SLC25 protein family.

N2OFF’s disclosures state that MitoCareX is advancing a precision oncology pipeline centered on mitochondrial SLC25 transport proteins involved in the metabolic reprogramming of aggressive cancers, including lung and pancreatic cancer. A core element of MitoCareX’s platform is MITOLINE™, a proprietary algorithm that supports reliable 3D comparative modeling of mitochondrial transport proteins and enables in silico screening of small molecules. Company communications explain that MitoCareX combines computational modeling with in vitro screening systems related to mitochondria to identify and validate small-molecule candidates with anti-cancer biological activity.

N2OFF’s later news releases refer to N2OFF as a drug discovery company that is also investing in solar energy assets, reflecting the significance of MitoCareX within the overall corporate profile. The company also highlights that MitoCareX’s scientific work focuses on mitochondrial carrier biology, with particular emphasis on the SLC25 family and its role in tumor metabolism and therapy resistance.

Save Foods Ltd. and post-harvest agri-tech

In multiple announcements, N2OFF states that it controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatments for fruits and vegetables. According to these disclosures, Save Foods’ technologies aim to reduce or prevent pathogen contamination in produce after harvest. Earlier descriptions of N2OFF’s business also referred to pathogen prevention and shelf-life extension as key activities, aligning with the focus of Save Foods on post-harvest treatment technologies.

An 8-K filed in January 2026 reports that N2OFF entered into a Securities Exchange Agreement with Voice Assist, Inc. under which N2OFF agreed to transfer all of the ordinary shares of Save Foods that it owns, representing approximately 98% of Save Foods’ issued and outstanding ordinary share capital. In exchange, N2OFF is to receive shares of Voice Assist common stock and additional consideration under a related services agreement. This transaction, once closed, would shift N2OFF’s exposure to Save Foods from direct majority ownership to an equity and services relationship with Voice Assist, while still tying potential future value to Save Foods–related activities through royalties and other consideration described in the services agreement.

Corporate actions and capital markets profile

N2OFF is incorporated in Nevada and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-40403. The company has disclosed several notable corporate and capital markets actions:

• A reverse stock split of its common stock at a ratio of one-for-thirty-five (1-for-35), effected through a Certificate of Amendment to its Amended and Restated Articles of Incorporation. Company communications explain that this reverse split was intended, among other things, to help regain compliance with Nasdaq’s minimum bid price requirement.
• Notifications from Nasdaq regarding regaining compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), following a period during which the company’s shares had traded below the required threshold.
• Unregistered sales of equity securities, including issuances of common stock under consulting agreements and equity compensation plans, as reported in Form 8-K filings.
• Annual and special meetings of stockholders addressing matters such as director elections, amendments to the company’s share incentive plan, approval of the MitoCareX acquisition, authorization of the reverse stock split, and approval of warrant-related share issuances.

Business evolution and multi-segment profile

Across its public disclosures, N2OFF presents an evolving business model that spans several areas:

• EU-based solar and energy storage assets developed under an RTB model in partnership with Solterra Renewable Energy Ltd. and related entities.
• Biotechnology and precision oncology through its wholly owned subsidiary MitoCareX Bio Ltd., which focuses on mitochondrial SLC25 transport proteins and uses the MITOLINE™ algorithm to support drug discovery.
• Post-harvest agri-tech through Save Foods Ltd., an Israeli company focused on treatments designed to control and prevent pathogen contamination in fruits and vegetables, with a planned transfer of N2OFF’s majority stake to Voice Assist, Inc. under a securities exchange agreement.

Earlier descriptions also characterized N2OFF as an agri-food tech company with reportable segments in pathogen prevention and N2O emissions global warming solutions. Subsequent filings and news emphasize cleantech, solar assets, and the integration of biotech drug discovery through MitoCareX, indicating a shift toward a multi-segment profile that combines renewable energy infrastructure and life sciences–oriented activities.

Regulatory filings and governance

N2OFF’s SEC filings, including multiple Forms 8-K and a definitive proxy statement on Schedule 14A, provide details on its corporate governance, shareholder votes, and material agreements. These documents describe the company’s Nevada incorporation, its use of share incentive plans, and its engagement of independent auditors. The filings also outline the terms of significant transactions, such as the acquisition of MitoCareX and the planned transfer of Save Foods shares to Voice Assist, as well as the structure of related consideration and service arrangements.